![](/img/cover-not-exists.png)
343 Cost-effectiveness of deferasirox in lower-risk myelodysplastic syndrome (MDS) in Canada
K. El Ouagari, K. Migliaccio-Walle, H. Lau, D. BozkayaVolume:
35
Year:
2011
Language:
english
Pages:
1
DOI:
10.1016/s0145-2126(11)70345-9
File:
PDF, 69 KB
english, 2011